Table 1 Patients’ characteristics
Age (years) | |
Median (range) | 65 (18–89) |
Gender | |
Male | 87 |
Female | 72 |
Performance status | |
0 | 139 |
1 | 17 |
2 | 3 |
Location of primary tumor | |
Right side | 39 |
Left side | 120 |
Histological type | |
Well, Moderately | 142 |
Poorly, Mucinous | 17 |
RAS status | |
Wild type | 63 |
Mutant type | 54 |
Unknown | 42 |
Detection of unresectable tumor | |
Synchronous | 106 |
Metachronous | 53 |
Number of organs affected by metastasis | |
One organ | 106 |
Multiple organs | 53 |
Peritoneal dissemination | |
Negative | 124 |
Positive | 35 |
First-line chemotherapy regimen | |
FOLFOX | 74 |
CapeOX | 52 |
FOLFIRI | 25 |
SOX | 8 |
Molecular-targeted therapy | |
Bevacizumab | 85 |
Cetuximab | 11 |
Panitumumab | 7 |
None | 56 |
BMI (kg/m2) | |
Median (range) | 21.71 (15.30–33.76) |
Serum albumin concentration (g/dl) | |
Median (range) | 3.9 (2.5–4.9) |
NLR | |
Median (range) | 2.41 (0.58–13.56) |
ALI | |
Median (range) | 37.92 (4.61–175.07) |